Analysis of Early Clinical Characteristics in 382 Patients with Novel Coronavirus Pneumonia

Objective To summarize the early clinical characteristics of patients with novel coronavirus pneumonia to provide a scientific basis for diagnosis and treatment of the condition. Method Retrospectively analyzes the clinical data of 382 patients confirmed as novel coronavirus pneumonia patients from January 24, 2020 to March 1, 2020. Comparing the general situation, clinical performance, laboratory inspection results of different clinical typing cases. Results of 382 patients hospitalized with novel coronavirus pneumonia, 285 (74.6 percent), 63 (16.5 percent), critical 34 (8.9 percent), 190 cases in men and 192 cases in women, average age (52.0±14.1), 124 (32.5 percent) patients combined with hypertension, diabetes, coronary heart disease, etc. Above the underlying diseases, the main Clinical manifestations were of 369 cases of fever (96.6%), 356 cases of cough (93.2%), 325 cases of weakness (85.1%), and differences in symptoms such as weakness, aerodynamic and thoracic stuffiness were statistically significant (both P<0.01), lymphocytes (L), albumin in heavy endangering heavy patients compared to common type patients (ALB) significantly lower (both P<0.01), heavy and Prothrombin time (PT) in critically heavy patients, activated partial thrombin time (APTT), D-dimer (D-Dimer), hypersensitivity C reactive protein (HCRP), hematoconiosis (ESR), tenion trysine aminotransferase (AST), beta-microglobulin (β2-MG), creatine kinase isozyase (CK), creatine (CK-MB), lactic acid dehydrogenase (LDH ), myocardial troponin I (CTNI) is significantly elevated over common types (both P<0.01). Conclusion COVID-19 patients are more likely to develop into heavy and critical, often concurrent with blood, clotting, liver, kidney, heart, etc., multidisciplinary cooperation should be strengthened in clinical treatment.